Clearmind Medicine Announces Innovative Patent Publication
Clearmind Medicine Inc. (Nasdaq: CMND), a pioneering clinical-stage biotech firm, has made significant strides in addressing addiction issues. The company announced the publication of a patent by the Korean Intellectual Property Office for a groundbreaking combination therapy involving MEAI and N-Acylethanolamines aimed at treating cocaine addiction.
Research Foundation for the Patent
This patent stems from compelling preclinical research conducted by Professor Gal Yadid and his team at a prominent brain research center. Their studies demonstrated that MEAI significantly lessened the cravings associated with cocaine in animal models. This discovery is integral in forming a basis for effective therapies combating substance addiction.
Important Findings in Animal Studies
Further investigations into MEAI's effects were conducted to ensure that its impact on drug-seeking behavior did not negatively influence natural rewards, which are crucial for survival. The results were promising: while MEAI successfully reduced cocaine-seeking behavior, it left the animals’ responses to natural rewards unchanged, indicating that its effects are specifically aimed at drug-related compulsions rather than disrupting overall reward systems.
Collaboration with SciSparc Ltd.
Clearmind’s innovative research efforts are part of a broader collaboration with SciSparc Ltd. (NASDAQ: SPRC), which focuses on developing therapies for central nervous system disorders. This partnership allows Clearmind to enhance its MEAI treatment with SciSparc’s PEA, leveraging complementary expertise to develop effective addiction therapies.
Company Overview: Clearmind Medicine Inc.
Founded to address severe and under-treated health issues, Clearmind specializes in developing psychedelic-derived therapeutic compounds. The company is committed to researching these novel treatments and working towards their commercialization as regulated medicines, foods, or supplements.
Intellectual Property Portfolio
Clearmind boasts an impressive intellectual property portfolio consisting of 19 patent families and 31 granted patents. The company remains proactive in seeking additional patents and acquiring new intellectual property to strengthen its position in the market.
Stock Market Presence
Investors can track Clearmind's performance on Nasdaq under the ticker symbol "CMND" and on the Frankfurt Stock Exchange with the symbol “CWY0.” The company’s shares are actively traded, reflecting its growing influence in the biotech sector.
Contact Information
For inquiries or further details regarding Clearmind Medicine and its breakthroughs, interested parties can reach out via:
Investor Relations: invest@clearmindmedicine.com
Telephone: (604) 260-1566
Frequently Asked Questions
What is MEAI?
MEAI is a novel psychedelic treatment being developed for addiction and mental health issues.
How does Clearmind's therapy work?
The therapy aims to reduce cravings for cocaine through the combination of MEAI and N-Acylethanolamines.
What is the significance of the new patent?
The patent validates Clearmind's innovative approach and enhances its competitive edge in developing treatments for addiction.
Who is involved in the research?
The research is led by experts such as Professor Gal Yadid and involves collaborations with SciSparc Ltd.
Where can I find more information about Clearmind Medicine?
More information is available on Clearmind's official website.
